India, July 31 -- Bayer AG updated its financial outlook following stronger-than-expected performance in its Pharmaceuticals division during the first half of the year. The company has established additional provisions of around 1.2 billion euros for the Roundup (glyphosate) litigation. This figure is included in the around 1.7 billion euros total.
Bayer generated Group sales of approximately 10.7 billion euros in the second quarter of 2025. Quarterly core earnings per share increased to 1.23 euros, mainly driven by a year-on-year improvement in the financial result and lower tax expense.
The company now projects full-year 2025 Group sales between 46 billion euros and 48 billion euros, up from its earlier forecast of 45 billion euros to 4...